胃旁路术后肠道在伴或不伴糖尿病缓解者β细胞功能时间变化中的作用
该前瞻性纵向研究在严重肥胖伴2型糖尿病者中评估Roux-en-Y胃旁路术(RYGB)后口服与静脉葡萄糖刺激下β细胞功能的时间变化,发现口服葡萄糖后β细胞葡萄糖敏感性的幅度与时间变化因糖尿病缓解状态而异,且术前β细胞功能及其术后变化可预测缓解,而体重下降和胰岛素敏感性不能。
要点
- RYGB后口服葡萄糖β细胞葡萄糖敏感性变化因缓解状态不同:完全缓解者升高6.5倍且持续,部分缓解者升高3.3倍但12个月后未持续,未缓解者升高2.7倍无统计学意义。
- 静脉葡萄糖后β细胞功能改善至12个月才显现,仅完全缓解者显著,幅度约为口服葡萄糖的33%。
- 术前β细胞功能及其术后变化预测糖尿病缓解,体重下降和胰岛素敏感性不预测。
核心结论
- RYGB后β细胞功能改善(而非体重下降或胰岛素敏感性变化)驱动糖尿病缓解。
研究设计与样本
- 纵向前瞻性研究,在严重肥胖伴2型糖尿病者中于RYGB术后0、3(n=29)、12(n=24)、24(n=20)个月评估口服葡萄糖摄入和分级葡萄糖输注后的β细胞功能,数据收集于2015至2019年在学术临床研究中心进行。
主要发现
- 术后体重、脂肪量、腰围和胰岛素抵抗下降(12和24个月均P<0.001)在糖尿病缓解状态间无差异。
- 口服葡萄糖后β细胞葡萄糖敏感性的幅度和时间变化因缓解状态而异(P=0.04):完全缓解者升高6.5倍(P<0.01)且持续,部分缓解者升高3.3倍(P<0.001)但12个月后未持续,未缓解者升高2.7倍(P无统计学意义)。
- 静脉葡萄糖后β细胞功能改善至12个月才显现,仅完全缓解者显著,幅度约为口服葡萄糖的33%。
- 术前β细胞功能及其术后变化预测缓解,体重下降和胰岛素敏感性不预测。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The role of the gut in diabetes remission after Roux-en-Y gastric bypass (RYGB) is incompletely understood. We assessed the temporal change in insulin secretory capacity after RYGB, using oral and intravenous (IV) glucose, in individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS: Longitudinal, prospective measures of β-cell function were assessed after oral glucose intake and graded glucose infusion in individuals with severe obesity and diabetes studied at 0, 3 (n = 29), 12 (n = 24), and 24 (n = 20) months after RYGB. Data were collected between 2015 and 2019 in an academic clinical research center. RESULTS: The decreases in body weight, fat mass, waist circumference, and insulin resistance after surgery (all P < 0.001 at 12 and 24 months) did not differ according to diabetes remission status. In contrast, both the magnitude and temporal changes in β-cell glucose sensitivity after oral glucose intake differed by remission status (P = 0.04): greater (6.5-fold; P < 0.01) and sustained in those in full remission, moderate and not sustained past 12 months in those with partial remission (3.3-fold; P < 0.001), and minimal in those not experiencing remission (2.7-fold; P = not significant). The improvement in β-cell function after IV glucose administration was not apparent until 12 months, significant only in those in full remission, and only ∼33% of that observed after oral glucose intake. Preintervention β-cell function and its change after surgery predicted remission; weight loss and insulin sensitivity did not. CONCLUSIONS: Our data show the time course of changes in β-cell function after RYGB. The improvement in β-cell function after RYGB, but not changes in weight loss or insulin sensitivity, drives diabetes remission.
引用
- Prasad M, Mark V, Ligon C, et al. Role of the Gut in the Temporal Changes of β-Cell Function After Gastric Bypass in Individuals With and Without Diabetes Remission. Diabetes Care. 2022. PMID: 34857533. doi:10.2337/dc21-1270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。